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Background: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung
cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. However,
resistance to erlotinib is a major clinical problem. Earlier we have demonstrated the role of Hedgehog (Hh)
signaling in Epithelial-to-Mesenchymal transition (EMT) of NSCLC cells, leading to increased proliferation and
invasion. Here, we investigated the role of Hh signaling in erlotinib resistance of TGF-β1-induced NSCLC cells that
are reminiscent of EMT cells.
Methods: Hh signaling was inhibited by specific siRNA and by GDC-0449, a small molecule antagonist of G protein
coupled receptor smoothened in the Hh pathway. Not all NSCLC patients are likely to benefit from EGFR-TKIs and,
therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant
EMT cells. Specific pre- and anti-miRNA preparations were used to study the mechanistic involvement of miRNAs in
drug resistance mechanism.
Results: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of
NSCLC cells to erlotinib and cisplatin. It also resulted in re-sensitization of TGF-β1-induced A549 (A549M) cells as
well the mesenchymal phenotypic H1299 cells to erlotinib and cisplatin treatment with concomitant up-regulation
of cancer stem cell (CSC) markers (Sox2, Nanog and EpCAM) and down-regulation of miR-200 and let-7 family
miRNAs. Ectopic up-regulation of miRNAs, especially miR-200b and let-7c, significantly diminished the erlotinib
resistance of A549M cells. Inhibition of Hh signaling by GDC-0449 in EMT cells resulted in the attenuation of CSC
markers and up-regulation of miR-200b and let-7c, leading to sensitization of EMT cells to drug treatment, thus,
confirming a connection between Hh signaling, miRNAs and drug resistance.
Conclusions: We demonstrate that Hh pathway, through EMT-induction, leads to reduced sensitivity to EGFR-TKIs
in NSCLCs. Therefore, targeting Hh pathway may lead to the reversal of EMT phenotype and improve the
therapeutic efficacy of EGFR-TKIs in NSCLC patients.
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Lung cancer is the most common cause of cancer re-
lated mortality in the United States [1]. The primary
reason for this poor outcome in non-small cell lung
cancer (NSCLC) patients is the presence of systemic
metastases at diagnosis in a high proportion patients
[2]. Recent studies have shown that the cellular pro-
gram of epithelial-to-mesencymal transition (EMT) pheno-
typic cells, involved in embryogenesis, is a critical step
in the development of metastases. EMT is character-
ized by a switch from an epithelial phenotype of polar-
ized cells with expression of epithelial markers such as
E-cadherin to a mesenchymal phenotype of cells that
lack polarity, are motile and have down regulation of
E-cadherin. Another important characteristic of EMT
cancer cells is resistance to existing cytotoxic and
targeted agents, including EGFR-TKI, erlotinib. Recent
data suggests that cancer cells with EMT phenotype
also demonstrate stem cell like features. Pre-clinical
studies suggest that measures to reverse EMT can en-
hance the therapeutic efficacy of erlotinib and other
drugs.
The hedgehog (Hh) signaling pathway is a crucial
mediator of normal organ development during em-
bryogenesis and tissue repair during wound healing,
specifically in the lung tissue. Hh pathway regulates
these processes through the induction of EMT. Re-
activation of the Hh pathway with induction of EMT is
increasingly being implicated in carcinogenesis of many
cancers. In addition, pre-clinical studies show that the in-
hibition of Hh pathway can reverse EMT, which in turn is
associated with enhanced tumor sensitivity to cytotoxic
agents. Several investigators have shown that the Hh path-
way is activated in many NSCLCs. We have earlier shown
that chronic exposure to TGF-β induces EMT in a NSCLC
cell line A549 leading to A549 cells with greater mesenchy-
mal features (A549M cells) [3]. Induction of EMT in
these cells was associated with activation of the Hh
pathway. With the knowledge that EMT is connected
to drug resistance and our own observation that Hh
signaling is involved in the regulation of EMT, we
questioned whether inhibition of Hh signaling can re-
verse the drug resistance of NSCLC cells. In our current
investigation, we investigated the effect of silencing of
Hh signaling, using siRNA as well as pharmacological
inhibitor GDC-0449, on drug sensitivity of NSCLC
cells. GDC-0449 (vismodegib) is a Hh pathway inhibi-
tor which was approved recently for the use in pa-
tients with basal cell carcinoma of the skin, a tumor
type that has activating mutations in the Hh pathway.
Here we report a novel role of Hh signaling in drug re-
sistance phenotype of NSCLC cells which mechanistically
involves the regulation of EMT-related microRNAs
(miRNAs).Materials and methods
Cell lines and reagents
The human lung adenocarcinoma cell lines A549 and
H1299 were purchased from the American Type Culture
Collection (Manassas, VA) and maintained according to
the American Type Culture Collection’s instructions. All
cells were cultured in 5% CO2–humidified atmosphere
at 37°C. The cell lines have been tested and authenticated
through the core facility (Applied Genomics Technology
Center at Wayne State University) by short tandem repeat
profiling using the PowerPlex 16 System from Promega.
A549 cells were treated with TGF-β1 (5 ng/ml) for 21 days
to generate A549M cells (EMT phenotypic cells). Cells
were treated with 20 nM GDC-0449 (Genentech) for 72
hours, before conducting individual assays. Antibodies
were purchased from following sources – Sox2, Nanog,
EpCAM (Cell Signaling Technology, Beverly, MA) and
β-actin (Sigma-Aldrich, St Louis, MO).
Small interfering RNA (siRNA) transfection
Small interfering RNA (siRNA) specific for Hh (Shh;
SHH Stealth RNAiTM siRNA) was purchased from
Invitrogen. As a nonspecific control siRNA, scrambled
siRNA duplex (Invitrogen) was used. Transfection was
done using Lipofectamine RNAiMAX Transfection Re-
agent (Invitrogen) following the manufacturer’s instruc-
tion. Shh was silenced by siRNA for 48 hours prior to
assay or treatment. Experiment was repeated, at least, three
times independently and representative data is reported.
miRNA transfections
Cells were seeded at 2.5 × 105 cells per well in six well
plates and transfected with appropriate anti-miRs/pre-
miRs or miRNA-negative controls at a final concentration
of 200 nM for each individual miRNA (Ambion) using
DharmaFECT1 transfection reagent (Dharmacon). After
2 days of transfection, cells were split and transfected
twice again before the use of these cells for specified
experiments.
Cell growth inhibition studies by MTT assay
Cells were seeded at 5 × 103 cells per 100 μl of culture
medium per well in 96-well plates. The number of viable
cells was assessed in six wells using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma).
Cells were treated with Hh inhibitor (GDC-0449) for 72
hours, or with siRNA specific for Shh for 48 hours. Next,
cells were treated with either Cisplatin or Erlotinib, at the
specified concentrations. Control cells received equivalent
amount of vehicle (0.1% DMSO) in culture medium.
After treatment, cells were incubated with MTT re-
agent (0.5mg/ml; Sigma) at 37°C for 2 h and then with
isopropanol at room temperature for 1 h. Spectrophoto-
metric absorbance of the samples was determined by an
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Durham, NC). Cell proliferation index was calculated
by assigning the vehicle-treated control cells a numer-
ical value of 100. All the treatments, in individual experi-
ments, therefore, represent fraction of viable proliferating
cells, relative to vehicle-treated respective controls. Results
were plotted as means ± SD of three separate experiments
having six determinations per experiment for each experi-
mental condition.Real-Time RT-PCR
For miRNA analysis, total RNA was isolated using the
mirVana miRNA isolation kit (Ambion). The levels of
miRNAs were determined using miRNA-specific Taqman
MGB probes from the Taqman MicroRNA Assay (Applied
Biosystems), as described previously [4]. The relative
amounts of miRNA were normalized to internal miRNA
controls RNU6B and RNU48.Western blot analysis
For Western blot analysis, cells were lysed in RIPA buf-
fer containing complete mini EDTA-free protease inhibi-
tor cocktail (Roche, Indianapolis, IN) and phosphatase
inhibitor cocktails 1 and 2 (Sigma-Aldrich, St. Louis, MO)
[4]. After resolution on 12% polyacrylamide gels under de-
naturing conditions, proteins were transferred to nitrocel-
lulose membranes, incubated with appropriate primary /
horseradish peroxidase-conjugated secondary antibodies
and visualized using chemiluminescence detection system
(Pierce, Rockford, IL).Data analysis
The experimental results presented in the figures are
representative of three or more independent observa-
tions. The data are presented as the mean values ± SE.
Values of p < 0.05 and lower were considered to be sta-
tistically significant.Figure 1 TGF-β1-induced EMT results in drug resistance phenotype. D
viability, after treatment with erlotinib (A) and cisplatin (B), compared to A
cisplatin for 72 hours and then subjected to MTT assay. The IC50 and IC90
individual figures. ND: IC90 could not be determined. *p<0.05.Results
Cells with mesenchymal phenotype (A549M) are more
resistant to EGFR-TKI erlotinib and cisplatin, compared to
parental A549 cells
EMT phenotypic cancer cells have been shown to ac-
quire drug resistance [5-8]. Our earlier data established
that A549 cells with mesenchymal phenotype (A549M
cells) acquire invasiveness in vitro as well as in vivo [3],
and, therefore, we started our current investigation with
the hypothesis that A549M cells should be more resist-
ant to therapeutic drugs because of their mesenchymal
phenotype. To test this hypothesis, we treated A549 and
A549M cells with increasing doses of erlotinib and cis-
platin for 72 h, and measured cell viability. We found
significantly higher number of proliferating A549M cells
than A549 cells (p<0.05) at all the tested doses of erlotinib
(Figure 1A) as well as cisplatin (Figure 1B), suggesting that
A549M cells are indeed more resistant to erlotinib or cis-
platin, consistent with the EMT phenotype. The IC50
values as well as the IC90 values for A549M cells were
significantly higher for erlotinib (Figure 1A) and cis-
platin (Figure 1B), further confirming their drug resist-
ance characteristics.
Inhibition of hedgehog signaling sensitizes mesenchymal
A549M cells to erlotinib and cisplatin
Next, we evaluated whether Hedgehog (Hh) inhibition
can sensitize A549M cells to erlotinib or cisplatin. We
first used siRNA approach and inhibited Shh, a ligand of
the Hh pathway to test whether the knock-down of
Shh sensitizes A549M cells to erlotinib and cisplatin.
A549M cells were transfected with Shh-specific siRNA,
control cells were transfected with scrambled siRNA
and the cells were treated with erlotinib or cisplatin.
Additionally, parental A549 cells were included in the
experiment to confirm comparatively increased resist-
ance of A549M cells to erlotinib and cisplatin. As pre-
viously shown [3], siRNA against Shh was found to
significantly down-regulate the expression of Shh. A549Mose–response curves shows that A549M cells exhibit increased cell
549 cells. Cells were treated with indicated concentrations of erlotinib/
values for different conditions are provided in the table within the
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in cell proliferation (p<0.05) when treated with erlotinib
(Figure 2A) and cisplatin (Figure 2B). To confirm the im-
pact of inhibition of Hh signaling on drug resistance,
we treated A549M cells with pharmacological inhibitor
GDC-0449 for 72 h, followed by treatment with erlotinib
or cisplatin, and the cell viability was assessed after 72 h of
treatment. A549M cells were more resistant to erlotinib
and cisplatin, compared to parental A549 cells, and
A549M cells treated with GDC-0449 showed reduced
cell proliferation (Table 1), as evidenced by lower IC50
of both the drugs in the cells pre-treated with GDC-0449.
This suggests that Hh inhibitor GDC-0449 sensitizes mes-
enchymal phenotypic cells to standard therapy. The re-
sults of GDC-0449 sensitization of A549M cells, at a few
selected doses of erlotinib (Figure 3A) and cisplatin
(Figure 3B) clearly show that the A549M cells pre-treated
with GDC-0449 are more sensitive to the drugs. It is inter-
esting to note that GDC-0449 was not able to sensitize
the parental A549 cells (Figure 3A-B),which may be due
to the fact that the parental cells do not express appre-
ciable levels of Shh.
For further validation of this finding, we performed
experiments using another cell line, the H1299 cell line,
a NSCLC cell line with mesenchymal phenotype. H1299
cells are known to be resistant to erlotinib and cisplatin
[9-11]. These cells were treated with GDC-0449 for 72 h
prior to treatments with erlotinib or cisplatin for 72 h,
similar to the experiments with A549M cells above.
H1299 cells pretreated with GDC-0449 showed reduced
cell proliferation when exposed to erlotinib (Figure 3C)
or cisplatin (Figure 3D) as well as reduced IC50 (Table 1),
compared to untreated H1299 cells, and these results
are consistent with the results obtained from A549M
cells (Figure 2, Table 1). We also confirmed the specific
role of the Hh ligand Shh in drug sensitivity of H1299
cells by using Shh siRNA knock-down prior to treatmentFigure 2 Knock-down of Shh sensitizes A549M cells to standard thera
treatment with erlotinib (A) and cisplatin (B) following Shh knock-down. C
si-RNA against Shh (A549M-siShh) for 48 hours and then with indicated
were included as a control to verify the induced resistance of A549M cells to
A549 cells. *p<0.05 and **p<0.01.with cisplatin or erlotinib. H1299 cells with Shh knock-
down showed decreased cell viability (Results not shown),
confirming the involvement of Shh in restoring sensitivity
to standard therapy. Furthermore, we treated H1299 cells
with GDC-0449 alone and combined the data with the ob-
servations in Figure 3 to analyze the combined effects of
GDC-0449 and erlotinib/cisplatin. As shown in Table 2,
the observed values significantly exceeded the expec-
ted theoretical values indicating a sensitizing effect of
GDC-0449, as opposed to a mere additive effect. Together,
these results indicate that treatment of NSCLCs with Hh
inhibitor prior to or concurrent with standard therapy
could improve sensitivity of NSCLCs with EMT features.
TGF-β1-induced EMT of NSCLC cells involves modulation
of Cancer Stem Cells (CSCs) and miRNAs
In order to fully understand the mechanism(s) of drug
resistance that accompany induction of EMT in NSCLC
cells, we investigated CSC markers (Sox2, Nanog and
EpCAM) and the expression levels of several EMT-related
miRNAs in parental A549 vs. mesenchymal A549M cells.
A comparison of levels of CSC markers, by western blot
analysis, revealed that the protein levels of CSC markers
are elevated in vehicle-treated control A549M cells
(Figure 4A). Since our earlier work has established a
mechanistic role of Hh signaling in EMT of these cells, we
treated A549M cells with GDC-0449 to inhibit Hh signal-
ing and found that, compared to levels in vector-treated
A549M cells, GDC-0449-treated cells had significantly re-
duced levels of CSCs (Figure 4A). As further molecular
signature of mesenchymal A549M cells, we investigated
some miRNAs that have been implicated in the EMT of
cancer cells. We chose two families of miRNAs, the
miR-200 and let-7 families, and our data revealed that sev-
eral member miRNAs of these EMT-regulating miRNA
families are down-regulated in the mesenchymal cells
(Figure 4B-C). In particular miR-200b and let-7c miRNAspies. Cell proliferation of A549M cells was significantly reduced after
ells were first treated with vehicle (A549M-control) or with specific
concentrations of erlotinib/cisplatin for 24 hours. Parental A549 cells
erlotinib/cisplatin. All the plotted values are relative to vehicle-treated
Table 1 GDC-0449 lowers the IC-50 of erlotinib/cisplatin





IC50 (μM) % Decrease
in IC50Without GDC With GDC
A549 Erlotinib 11.56 11.27 2.51
Cisplatin 4.11 4.04 1.70
A549M Erlotinib 43.64 15.76 63.89
Cisplatin 36.16 9.64 73.34
H1299 Erlotinib 10.57 7.20 31.90
Cisplatin 12.15 4.19 65.56
Cells were pre-treated with 20nM GDC-0449 (GDC) for 72 h or vehicle control,
prior to treatments with increasing doses of erlotinib or cisplatin for 72 h.
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miRNAs from the two respective families. These results
are consistent with the documented epithelial phenotype
promoting role of these two miRNA families.
Re-expression of selected miRNAs can reverse TGF-β1
-induced drug resistance
Having observed differential expression of several miRNAs
in parental A549 vs. A549M cells, we next assessed
whether these miRNAs are mechanistically involved in
the drug resistance associated with the TGF-β1-inducedFigure 3 Hedgehog inhibitor, GDC-0449 (GDC) sensitizes A549M as w
GDC-0449 (20nM) markedly reduced cell proliferation of A549M cells (A549
vehicle treated respective control cells, when they were exposed to erlotin
sensitization (A-B). All the plotted values are relative to vehicle-treated cellmesenchymal phenotype. Since the response to erlotinib
and cisplatin was similar in our earlier experiments, we
chose erlotinib for these mechanistic studies. A549M cells
were transfected with pre-miRNAs for the re-expression
of chosen miRNAs and to test whether re-constitution of
these miRNAs can reverse the drug resistance. We found
that the re-expression of different miRNAs did reverse the
drug resistance of A549M cells (Figure 5). Firstly, we
transfected A549M cells with a cocktail of pre-miR-200a+
pre-miR-200b+pre-miR-200c and observed 23.77% inhib-
ition of TGF-β1-mediated effect on erlotinib resistance
(Figure 5A-B). From the let-7 family, we chose let-7b and
let-7c for re-expression because they were the most-
down-regulated miRNAs from their family in A549M
cells. Re-expression of these miRNAs resulted in slightly
more inhibition (29.76%) of TGF-β1-mediated effect on
erlotinib resistance (Figure 5A-B). Finally, we re-expressed
the top most down-regulated miRNAs from both families
and transfected A549M cells with a cocktail of pre-miR-
200b+pre-let-7c. We found much more potent inhibition
(67.69%) of TGF-β1-mediated effect on erlotinib resist-
ance (Figure 5A-B). We also confirmed the reversal of
EMT by pre-miR-200b+let-7c treatment and the results of
real time RT-PCR are shown as Figure 5C. Pre-treatment
with miR-200b+let-7c significantly abrogated the inhibitionell as H1299 cells to standard therapies. Pre-treatment with
M-GDC) (A-B) as well as H1299 cells (H1299-GDC) (C-D), compared to
ib or cisplatin for 72 hours. Control A549 cells did not exhibit such
s.
Table 2 GDC-0449 sensitizes H1299 cells to erlotinib/cisplatin
Erlotinib (A)10 μM GDC (B)20 nM Erlotinib + GDC [Expected (A+B)] Erlotinib + GDC [Observed]
48.00 ± 1.8 12.81 ± 0.7 60.81 ± 1.9 68.60 ± 1.1
Cisplatin (C)9.9 μM GDC (B)20 nM Cisplatin + GDC [Expected (C+B)] Cisplatin + GDC [Observed]
46.14 ± 3.1 12.81 ± 0.7 58.95 ± 2.8 71.93 ± 2.4
The inhibition by erlotinib (A) and cisplatin (C) was calculated from the experiment shown in Figure 3C-D and all the values represent % Inhibition of H1299 cell
proliferation under specified treatments. Erlotinib/cisplatin as well as GDC-0449 (GDC) (B) inhibited cell proliferation individually and the combination was
significantly more effective.
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(Figure 5C), all of which are indications of the reversal of
EMT.
miRNAs that reverse TGF-β1-induced drug resistance also
play a role in GDC-0449’s inhibition of erlotinib resistance
Our results thus far indicated a role of miR-200b and
let-7c in TGF-β1-induced EMT that results in resistance
to erlotinib. With our focus on mechanistic involvement
of Hh signaling in this process, we next tested the effect, if
any, of GDC-0449 on these miRNAs. Exposure to GDC-
0449 for 72 h resulted in a significant up-regulation
(p<0.05) of both the miRNAs in A549M cells (Figure 6A)
which might explain the increased sensitivity of cells to
erlotinib after GDC-0449 treatment. To verify this, we
down-regulated miRNAs, by using commercially availableFigure 4 Modulation of CSC markers and miRNAs accompanies EMT o
markers Sox2, Nanog and EpCAM and GDC-0449 inhibited such TGF-β-indu
changes in the expression levels of (B) miR-200 family and (C) let-7 family
which the data was normalized. *p<0.05 and **p<0.01.specific anti-miRs, in GDC-0449 treated A549-M cells,
followed by treatment with erlotinib. We found that the
down-regulation of miRNAs abrogated the GDC-0449-
induced sensitization of A549M cells to erlotinib treat-
ment (Figure 6B). Whereas down-regulation of miR-200
family abrogated GDC-0449 effect by 51.06%, let7-b/c
could abrogate this effect by only 23.40% (Figure 6C).
Down-regulation of miR-200b+let-7c was found to be the
most effective with 78.72% inhibition of GDC-0449 effect
(Figure 6C).
Discussion
The major findings of our study are – a) TGF-β1-induced
EMT of NSCLC cells leads to increased resistance to both
erlotinib and cisplatin; b) Hh signaling seems to play
a role in such EMT-induced drug resistance becausef NSCLC cells. (A) A549M cells exhibit increased expression of CSC
ced expression of CSC markers. TGF-β1-induced EMT also involved
of miRNAs. RNU6B and RNU48 were used as miRNA controls against
Figure 5 Mechanistic role of miRNAs in TGF-β1 induced drug resistance. (A) Re-expression of miR-200s and let-7s sensitized A549M cells to
erlotinib treatment. (B) Data from Figure 5A was used to calculate the extent of sensitization by re-expression of miRNAs upon erlotinib
treatment, as measured by % inhibition of A549M resistance compared to parental A549 cells. (C) Re-expression of miR-200b+let-7c reversed EMT.
E-cadherin and ZEB1 mRNA levels were determined by real time RT-PCR using GAPDH as the internal control. All the plotted values in Figure 5A
are relative to vehicle-treated A549 cells. RNU6B and RNU48 were used as miRNA controls against which the data was normalized. *p<0.05.
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regulation of Hh signaling inhibits resistance to both
the drugs and c) EMT regulating miRNAs such as
miR-200b and let-7c are mechanistically involved in Hh
signaling- and EMT-mediated resistance of NSCLC cells
to TKI erlotinib.
Resistance to currently available anti-cancer drugs such
as erlotinib represents a major clinical challenge [12]. A
number of investigational tools such as gene expression,Figure 6 Mechanistic role of miRNAs in GDC-0449 effects on drug res
let-7c, the two top regulated miRNAs in their respective families. (B) Down
GDC-0449 mediated inhibition of erlotinib resistance in A549M cells. (C) Da
effect through the use of anti-miRNAs, as measured by % inhibition of A54
plotted values in Figure 6B are relative to vehicle-treated A549M cells and
with 10μM erlotinib. RNU6B and RNU48 were used as miRNA controls agaixenograft assays and proteomic profiling techniques have
been used to find biomarkers associated with sensitiv-
ity to erlotinib in a panel of sensitive and insensitive
NSCLC cell lines [9,13,14]. These studies reported that
sensitive cell lines express well-established epithelial
markers E-cadherin and catenin as well as exhibit the
typical cobblestone epithelial morphology and tight
cell–cell junctions of epithelial cells. On the other hand, in-
sensitive cell lines express characteristics of mesenchymalistance. (A) GDC-0449 up-regulated the expression of miR-200b and
-regulation of miR-200 and let-7 family miRNAs abrogated the
ta from Figure 6B was used to calculate the abrogation of GDC-0449
9M sensitivity to GDC-0449, compared to control A549M cells. All the
the first bar in the same figure represents A549M cells treated only
nst which the data was normalized. *p<0.05.
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ZEB1, consistent with more fibroblastic scattered morph-
ology. In summary, these results are suggestive of the
process of EMT as an indicator of sensitivity to EGFR in-
hibitors. Moreover, a study by Prudkin et al. has indicated
an association with these EMT markers in the sequential
pathogenesis of squamous cell carcinoma [15], suggesting
that the combination of EGFR-TKI with the inhibitor of
EMT-inducing-molecules could become a novel approach
toward the treatment of lung cancer, especially for NSCLC.
The hedgehog (Hh) signaling pathway is involved in
embryogenesis particularly in the development of the
lungs. This pathway is not active in adult tissues but it
can be activated in many cancers including NSCLC
[16-19]. In addition, blocking Hh signaling inhibits the
growth, invasion and metastasis of cancer cells, which
is associated with the down-regulation of Snail and up-
regulation of E-cadherin. Also, over-expression of
GLI1, the effector molecule of the Hh signaling path-
way, in epithelial cells, leads to an aggressive pheno-
type with down-regulation of E-cadherin [20,21]. All of
this evidence suggests a connection between Hh sig-
naling and EMT which can potentially be exploited for
therapy.
Based on the available literature discussed above, there
seems to be a correlation between EMT, drug resistance
and Hh signaling but the mechanistic details of this
inter-relationship is not clearly understood. We have
previously shown that there is a transcriptional up-
regulation of Shh by TGF-β1 as a key step during the in-
duction of EMT in NSCLC cell line [3]. As the next step,
we now provide evidence in support of the role for Hh sig-
naling pathway in drug resistance phenotype of NSCLC
cells that accompanies the processes of EMT. Our results
show an increase in resistance to drugs when EMT is in-
duced in NSCLC cells that are chronically exposed to
TGF-β1. Resistance was enhanced to both cisplatin and
erlotinib. A similar response of EMTcells to these two dif-
ferent drugs suggests a broader role of EMT in drug re-
sistance that might not be confined to any particular class
of anti-cancer drugs.
With the increased resistance of EMT cells to drugs,
reversal of EMT for the re-sensitization of such cells is
very intuitive. The challenge, however, lies in the eluci-
dation of the regulation of EMT which can potentially
help identify novel targets for therapy and reversal of
EMT. Taking a cue from our previous work, we investi-
gated Hh signaling in relation to EMT-induced drug re-
sistance. As a proof-of-principle, we inhibited Shh by
siRNA in NSCLC cells that had undergone EMT, and
this resulted in re-sensitization of NSCLC cells to erlotinib
and cisplatin. To make our results clinically relevant, we
used a pharmacological inhibitor of Hh signaling, GDC-
0449, and obtained very similar results. These resultsclearly demonstrate the relevance of inhibition of Hh sig-
naling for reversal of EMT and overcoming drug resist-
ance. In addition to the TGF-β1-induced EMT as a model,
we confirmed our results in H1299 cells that have a dom-
inant mesenchymal phenotype and also exhibit elevated
levels of Shh. Re-sensitization of H1299 cells to erlotinib
and cisplatin was observed after treatment with GDC-
0449 further supports our hypothesis that reversal of
EMT through down-regulation of Hh signaling is an ef-
fective strategy to overcome drug resistant phenotype.
Since acquired resistance to conventional therapies is
a major clinical concern, re-sensitization of tumors of-
fers a viable alternative in the absence of novel thera-
peutic options. Different ‘sensitizing’ agents have been
investigated for their ability to reverse drug resistance
[22-25]. Of interest, re-sensitization to erlotinib [26-28]
as well as cisplatin [24,29] has been demonstrated. In a
recent study [24], miR-98 has been shown to sensitize
cisplatin-resistant human lung adenocarcinoma cells.
The miR-98 belongs to let-7 family of miRNAs and was
down-regulated in resistant cells. These results are in
agreement with our own observations where we found
reduced levels of let-7 family members in erlotinib and
cisplatin resistant cells. In a very recent report [30], the
role of let-7c in determining docetaxel resistance in lung
cancer model has been described. This further provides
evidence in support of the role of miRNAs, particularly
let-7c in a broader drug resistance phenotype with func-
tional implications, and these results are consistent with
our findings using a different class of drugs. In addition
to let-7 family, we observed down-regulation of miR-200
family and, collectively, this underlines a role of EMT-
regulating miRNAs in erlotinib/cisplatin resistance. In
experiments involving combination of agents/drugs, a
distinction between additive vs. sensitization effects is al-
ways a concern. The combined effects of Hh inhibition
and erlotinib/cisplatin were found to be significantly
more than the individual or simple additive effects,
which is reminiscent of sensitization. Furthermore, pre-
treatment of resistant A549M cells with GDC-0449
significantly lowered the IC50 values of erlotinib and
cisplatin, almost to the levels of sensitive parental
A549 cells, which further confirms re-sensitization.
We observed increased expression of CSC markers
and modulation of miRNAs (miR-200s and let7s) in
NSCLC cells with TGF-β1-induced EMT. The role of
CSCs in drug resistance of lung cancer cells has been
demonstrated [31,32]. Our results showed a significant
down-regulation of CSC markers Sox2, Nanog and
EpCAM upon inhibition of Hh signaling in A549-M
cells by GDC-0449, which provided direct evidence in
support of the connection between Hh signaling and
CSCs in a model system with induced EMT. Further,
miR-200 and let-7 families of miRNAs are well known
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sion and metastasis of lung cancer cells [10,35-37] fully
supports their established biological activity. As expected,
we observed down-regulation of these miRNAs in
TGF-β1-treated cells (A549M cells). Re-expression of
these miRNAs, especially re-expression of the most
down-regulated miRNAs, miR-200b and let-7c, inhibited
the TGF-β1-mediated resistance of NSCLC cells to
erlotinib. Interestingly, we observed a direct induction
of these two-miRNAs by Hh inhibitor GDC-0449 treat-
ment. Additionally, re-expression of these two miRNAs
significantly reversed EMT markers. This could explain
the observed inhibition of TGF-β1-induced effects by
GDC-0449. It appears that TGF-β1 mediated induction of
EMT is in part mediated by down-regulation of miR-200
and let-7 family miRNAs and contributes to drug resist-
ance. The ability of GDC-0449 to maintain the levels,
through direct up-regulation of these miRNAs, abrogates
the TGF-β1-induced EMT, resulting in drug resistance. It
is also interesting to note that the modulation of multiple
members of the same miRNA family, either miR-200
family or the let-7 family, did influence the TGF-β1/GDC-
0449 effects but not to the same extent as the combin-
ation of miR-200b and let-7c. This can probably be
explained by the fact that multiple members of the
same miRNA family have overlapping target genes and
concurrently targeting miRNAs from different families
can be more effective through their combined effects
on wide range of mutually exclusive targets.
In summary, our present studies established a mech-
anistic role of Hh signaling in EMT-associated drug re-
sistance phenotype of NSCLC cells which is mediated
through novel regulation of CSCs and the EMT. There-
fore, the inhibition of Hh signaling could be a useful
approach for reducing tumor aggressiveness in NSCLC,
and as such, the reversal of EMT, particularly through
modulation of miRNAs, could also be useful for re-
sensitization of drug-resistant NSCLC cells to conven-
tional therapeutics, which would likely contribute to
improved survival of patients who rightfully deserve
better treatment outcomes.
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